
The Swiss hearing aid manufacturer Sonova has announced its results from the skewed financial year 2021/2022, surpassing expectations in several key areas, it reports in its financial results from the period on Monday.
A favorable basis for comparison secured a significant advance in figures compared to the same period last year, as the first half of 2021/2022 was characterized by a recovery of market conditions for hearing aids prior to the Covid-19 pandemic, though some challenges still remain.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.